Intriguingly, a second dose of EGFRvIII-targeted or B7-H3-targeted CAR-T cells failed to control tumor growth, whereas FLAG-tag-targeted CAR-T cells delayed intracranial tumor progression and extended animal survival to a certain extent (Fig. 3d–i). This evidence concerns the gene CD276 and neoplasm.